Advertisement

Journal of Endocrinological Investigation

, Volume 22, Issue 4, pp 306–309 | Cite as

Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline

  • S. Cannavò
  • L. Bartolone
  • A. Blandino
  • S. Spinella
  • S. Galatioto
  • F. Trimarchi
Case Report

Abstract

Cabergoline decreases both serum PRL levels and size of prolactinomas, including some tumors resistant to other dopamine-agonists. It is common observation that the shrinkage of the adenoma is preceded by suppression of PRL levels. A minority of patients, who do not show a significant decrease of PRL after a short trial with dopamine-agonists, undergoes neurosurgery or radiotherapy. We report on the case of a 14-year-old girl with a huge prolactinoma who showed, during cabergoline treatment (0.5 mg twice a week), a significant shrinkage of the pituitary mass but no decrease of the very high PRL values. She was referred to us after partial removal of the suprasellar extension of the pituitary tumor. The post-surgical evaluation showed very high PRL levels (9352 μg/l; 20941 μg/l before surgery), which did not decrease during the 2-year treatment with cabergoline (nadir value: 8735 μg/l). However, one month after the beginning of therapy, MRI showed a significant shrinkage of the tumor (tumor volume 5.7 ml, compared with 45.1 ml prior to surgery and 24.4 ml after surgery). Subsequently MRIs demon-strated a progressive reduction of the size with a complete disappearance of the suprasellar and parasellar tissue (tumor volume 1.8, 0.9 and 0.2 ml, at 3, 6 and 12 months, respectively). The MRI performed at the 24th month showed a secondary empty sella, with residual tumor tissue in the right sphenoidal sinus. Increasing cabergoline, up to 3 mg a week, failed to induce any decrease of PRL levels. In conclusion, in such macroprolactinomas the shrinkage of tumor is not strictly correlated with (or it is partially dissociated from) the inhibition of PRL hypersecretion. The choice of other therapeutic options in cabergoline-resistant macroprolacti-nomas needs careful neuroradiological evaluation after a short trial of pharmacological treatment.

Key-words

Pituitary adenoma prolactin cabergoline MRI hypopituitarism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Colao A., Di Sarno A., Sarnachiaro F., Ferone D., Di Renzo G., Merola B., Annunziato L., Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 1997, 82: 876.PubMedCrossRefGoogle Scholar
  2. 2.
    Muratori M., Arosio M., Gambino G., Romano C., Biella O., Faglia G. Use of cabergoline in the long-term treatment of hy-perprolactinemic and acromegalic patients. J. Endocrinol. Invest. 1997, 20: 537.PubMedGoogle Scholar
  3. 3.
    Ferrari C., Abs R., Bevan J.S., Brabant G., Ciccarelli E., Motta T., Mucci M., Muratori M., Musatti L., Verbessem G., Scanlon M.F. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin. Endocrinol. (Oxf.) 1997, 46: 409.CrossRefGoogle Scholar
  4. 4.
    Cai W.Y., Alexander J.M., Hedley-Whyte E.T., Scheithauer B.W., Jameson J.L., Zerves N.T., Klibanski A. Ras mutations in human prolactinomas and pituitary carcinomas. J. Clin. Endocrinol. Metab. 1994, 78: 89.PubMedGoogle Scholar
  5. 5.
    Molitch M.E., Thorner M.O., Wilson C. Management of prolactinomas. J. Clin. Endocrinol. Metab. 1997, 82: 996.PubMedCrossRefGoogle Scholar
  6. 6.
    Ballarè E., Mantovani S., Lania A., Spada A. G proteins in human pituitary adenomas. J. Endocrinol. Invest. 1996, 19 (Suppl. to n. 5): 2.Google Scholar
  7. 7.
    Caccavelli L., Morange-Ramos I., Kordon C., Jaquet P., Enjalbert A. Alteration of Ga subunit mRNA levels in bromocrip-tine resistant prolactinomas. J. Neuroendocrinol. 1996, 8: 737.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1999

Authors and Affiliations

  • S. Cannavò
    • 1
  • L. Bartolone
    • 1
  • A. Blandino
    • 2
  • S. Spinella
    • 3
  • S. Galatioto
    • 3
  • F. Trimarchi
    • 1
  1. 1.Cattedra di EndocrinologiaUniversity of MessinaMessinaItaly
  2. 2.Istituto di RadiologiaUniversity of MessinaItaly
  3. 3.Dipartimento di Patologia UmanaUniversity of MessinaItaly

Personalised recommendations